Jury still out on routine dementia screening for seniors

March 26, 2014 by Steven Reinberg, Healthday Reporter
Jury still out on routine dementia screening for seniors
Panel says benefits unproven, but Alzheimer's experts say early detection is important.

(HealthDay)—There's not yet enough evidence to support screening all older adults for dementia or a less severe condition called "mild cognitive impairment," according to a statement released Monday by the influential U.S. Preventive Services Task Force.

Mild cognitive impairment is a type of mental decline that does not interfere with activities of daily life.

General screening tests for dementia typically involve health professionals asking patients to perform a series of tasks to assess memory, attention, language, and visual-spatial and executive function.

"We found there wasn't sufficient evidence to recommend for or against screening," said member Dr. Douglas Owens, a professor of medicine at Stanford University's Center for Health Policy.

"This recommendation applies to people who are completely free of symptoms," Owens said. "If someone has symptoms, they should be evaluated—that's not screening in the sense we are talking about. We are talking about screening for people who have no symptoms whatsoever."

Screening all older adults for dementia or mild would only be worthwhile if there were meaningful treatments, Owens said.

"There would need to be interventions that you can do where the benefits would outweigh the harms," he said.

Currently, the benefits of available treatments are "modest to small," Owens said, "and how important those are clinically is uncertain."

More research is needed on how early detection of could help , their families and their doctors, Owens said.

The new statement, published online March 24 in the journal Annals of Internal Medicine, is the final recommendation, and updates the task force's draft recommendation released in November 2013.

One expert, however, suggested that the task force's recommendation is dodging a very important issue—an epidemic of dementia.

"Like Medicare's decision not to cover [a brain scan for Alzheimer's], the bottom line here is a cost-effectiveness analysis," said Dr. Sam Gandy, director of the Center for Cognitive Health at Mount Sinai Hospital in New York City. "In other words, since we have no effective treatment, we should not spend money on proactive diagnosis of dementia," he said.

Nicole Raisch, a spokeswoman for the USPSTF, took issue with Gandy's statement, however.

"The Task Force's recommendations are based solely on an assessment of the evidence, weighing both the benefits and harms of a preventive service," she said. "The Task Force does not consider the costs of providing a service in its appraisal of the effectiveness of a preventive service."

According to Gandy, many doctors avoid diagnosing dementia because, among other reasons, discussion of a dementia diagnosis with patients and family "is time consuming and the outlook is hopeless."

"The task force's advice that we look the other way can be interpreted as providing justification for this practice and misses an opportunity to elevate the conversation on dementia," he said.

Gandy said a recent report found that Alzheimer's may kill six times as many people as previously believed.

"This figure came as no surprise to dementia specialists," he said. "As long as primary-care physicians and other professionals fail to confront the epidemic status of dementia, the more time will be required before governments take seriously the economic threat of the dementia epidemic."

Heather Snyder, director of medical and scientific operations at the Alzheimer's Association, said there is value in detecting dementia early, despite the task force's stance.

"Their recommendation is that they can't make a recommendation," she said. "It's very important to separate insufficient evidence from no evidence."

The Alzheimer's Association supports early detection and diagnosis of Alzheimer's, Snyder said. "We know there is a better chance that an individual would be able to benefit from the current medications that are available," she said. "They would be able to take advantage of clinical trials and participate in conversations with their family about planning for their care and financial future."

According to the task force, dementia affects approximately 2.4 million to 5.5 million Americans. It results in trouble remembering, speaking, learning new things, concentrating and making decisions that affect daily life.

Alzheimer's disease is one type of dementia. Mental decline is not always as severe as Alzheimer's.

A recent study, published in the March/April edition of the journal Annals of Family Medicine, found that only about 20 percent of people who experience will go on to develop serious brain-related disorders such as Alzheimer's.

Although some people will be stricken with Alzheimer's or other , many will see their symptoms remain the same or disappear, the researchers said.

The U.S. Preventive Services Task Force is an independent, volunteer panel of experts in prevention- and evidence-based medicine. It makes recommendations about clinical preventive services such as screenings, counseling and medications.

Explore further: USPSTF: Evidence lacking for cognitive impairment screening

More information: For more about dementia, visit the U.S. National Library of Medicine.

Related Stories

USPSTF: Evidence lacking for cognitive impairment screening

November 5, 2013
(HealthDay)—The U.S. Preventive Services Task Force (USPSTF) has found that the evidence is insufficient to assess the balance of benefits and harms of cognitive impairment screening for older adults without signs or symptoms ...

USPSTF: Evidence lacking for cognitive impairment testing

October 22, 2013
(HealthDay)—Screening instruments can detect dementia but there is insufficient evidence to determine the clinical effect of screening and interventions, according to a review conducted for the U.S. Preventive Services ...

No routine mental tests for seniors—at least not yet, panel says

November 5, 2013
(HealthDay)—Physicians give screening tests to older adults who show signs of mental decline, and some experts have theorized that all seniors might benefit from routine memory testing. But proposed guidelines from a U.S. ...

USPSTF identifies high priority evidence gaps for older adults

November 20, 2013
(HealthDay)—The U.S. Preventive Services Task Force (USPSTF) has produced their third annual report for Congress identifying high-priority evidence gaps specifically relating to the care of older adults.

About one-quarter of patients with MCI progress to dementia

March 12, 2014
(HealthDay)—About 22 percent of patients with mild cognitive impairment (MCI) progress to dementia within three years, and depression symptoms modify the prognosis, according to a study published in the March/April issue ...

Alzheimer's prevention trial to evaluate, monitor participants' reactions to learning of higher disease risk status

March 19, 2014
A new clinical trial will soon begin testing whether early medical intervention in people at risk for Alzheimer's can slow down progression of disease pathology before symptoms emerge, as outlined in Science Translational ...

Recommended for you

Alzheimer's disease: Neuronal loss very limited

January 17, 2018
Frequently encountered in the elderly, Alzheimer's is considered a neurodegenerative disease, which means that it is accompanied by a significant, progressive loss of neurons and their nerve endings, or synapses. A joint ...

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

Advances in brain imaging settle debate over spread of key protein in Alzheimer's

January 5, 2018
Recent advances in brain imaging have enabled scientists to show for the first time that a key protein which causes nerve cell death spreads throughout the brain in Alzheimer's disease - and hence that blocking its spread ...

Molecular mechanism behind HIV-associated dementia revealed

January 5, 2018
For the first time, scientists have identified and inhibited a molecular process that can lead to neurodegeneration in patients with HIV, according to a Northwestern Medicine study published in Nature Communications.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.